Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies Posted byZacks Equity Research January 7, 2022 Leave a comment on Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.